Previous 10 | Next 10 |
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the de...
-- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis -- CHESTERBROOK, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a b...
OLINVYK, oliceridine, is Trevena's first approved drug and offers a compelling safety, efficacy, and economic profile versus IV morphine. Revenue growth looks particularly strong, with the potential for triple-digit growth rates in a multi-billion dollar market opportunity. Valuat...
Trevena, Inc. (TRVN) Q1 2021 Earnings Conference Call May 06, 2021, 08:00 ET Company Participants Barry Shin - SVP & CFO Carrie Bourdow - President, CEO & Director Robert Yoder - SVP & Chief Commercial Officer Mark Demitrack - SVP & Chief Medical Officer Conference Call Partic...
The following slide deck was published by Trevena, Inc. in conjunction with this event. For further details see: Trevena Investor Presentation - Slideshow
Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospital Services (AMS) +28%...
Trevena (TRVN): Q1 GAAP EPS of -$0.06 beats by $0.02.Revenue of $0.21M misses by $0.57M.Cash and cash equivalents were $97.7 million as of March 31, 2021, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through...
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , ...
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and cognitive function TRV027 selected for two large, multi-site COVID-19 studies le...
Trevena has been on my watch list for a few years, but my buy conditions were never aligned. Now, I am looking to start a small position in TRVN. The company's flagship product, OLINVYK, was launched back in January of this year. I don't expect the company to report impressive numbers...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...